Development of preclinical and clinical models for immune-related adverse events following checkpoint immunotherapy: a perspective from SITC and AACR

Guardado en:

Detalles Bibliográficos
Autores principales:	Theresa L Walunas, Lisa H Butterfield, William J Murphy, Elizabeth M Jaffee, Bart O Roep, Nicholas L Bayless, Jeffrey A Bluestone, Samantha Bucktrout, Christian A Koch, Arlene H Sharpe
Formato:	article
Lenguaje:	EN
Publicado:	BMJ Publishing Group 2021
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/2c74437288b04a82a1e4c572de4bdb74
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:2c74437288b04a82a1e4c572de4bdb74
record_format	dspace
spelling	oai:doaj.org-article:2c74437288b04a82a1e4c572de4bdb742021-11-05T06:00:07ZDevelopment of preclinical and clinical models for immune-related adverse events following checkpoint immunotherapy: a perspective from SITC and AACR10.1136/jitc-2021-0026272051-1426https://doaj.org/article/2c74437288b04a82a1e4c572de4bdb742021-09-01T00:00:00Zhttps://jitc.bmj.com/content/9/9/e002627.fullhttps://doaj.org/toc/2051-1426Theresa L WalunasLisa H ButterfieldWilliam J MurphyElizabeth M JaffeeBart O RoepNicholas L BaylessJeffrey A BluestoneSamantha BucktroutChristian A KochArlene H SharpeBMJ Publishing GrouparticleNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENJournal for ImmunoTherapy of Cancer, Vol 9, Iss 9 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Theresa L Walunas Lisa H Butterfield William J Murphy Elizabeth M Jaffee Bart O Roep Nicholas L Bayless Jeffrey A Bluestone Samantha Bucktrout Christian A Koch Arlene H Sharpe Development of preclinical and clinical models for immune-related adverse events following checkpoint immunotherapy: a perspective from SITC and AACR
format	article
author	Theresa L Walunas Lisa H Butterfield William J Murphy Elizabeth M Jaffee Bart O Roep Nicholas L Bayless Jeffrey A Bluestone Samantha Bucktrout Christian A Koch Arlene H Sharpe
author_facet	Theresa L Walunas Lisa H Butterfield William J Murphy Elizabeth M Jaffee Bart O Roep Nicholas L Bayless Jeffrey A Bluestone Samantha Bucktrout Christian A Koch Arlene H Sharpe
author_sort	Theresa L Walunas
title	Development of preclinical and clinical models for immune-related adverse events following checkpoint immunotherapy: a perspective from SITC and AACR
title_short	Development of preclinical and clinical models for immune-related adverse events following checkpoint immunotherapy: a perspective from SITC and AACR
title_full	Development of preclinical and clinical models for immune-related adverse events following checkpoint immunotherapy: a perspective from SITC and AACR
title_fullStr	Development of preclinical and clinical models for immune-related adverse events following checkpoint immunotherapy: a perspective from SITC and AACR
title_full_unstemmed	Development of preclinical and clinical models for immune-related adverse events following checkpoint immunotherapy: a perspective from SITC and AACR
title_sort	development of preclinical and clinical models for immune-related adverse events following checkpoint immunotherapy: a perspective from sitc and aacr
publisher	BMJ Publishing Group
publishDate	2021
url	https://doaj.org/article/2c74437288b04a82a1e4c572de4bdb74
work_keys_str_mv	AT theresalwalunas developmentofpreclinicalandclinicalmodelsforimmunerelatedadverseeventsfollowingcheckpointimmunotherapyaperspectivefromsitcandaacr AT lisahbutterfield developmentofpreclinicalandclinicalmodelsforimmunerelatedadverseeventsfollowingcheckpointimmunotherapyaperspectivefromsitcandaacr AT williamjmurphy developmentofpreclinicalandclinicalmodelsforimmunerelatedadverseeventsfollowingcheckpointimmunotherapyaperspectivefromsitcandaacr AT elizabethmjaffee developmentofpreclinicalandclinicalmodelsforimmunerelatedadverseeventsfollowingcheckpointimmunotherapyaperspectivefromsitcandaacr AT bartoroep developmentofpreclinicalandclinicalmodelsforimmunerelatedadverseeventsfollowingcheckpointimmunotherapyaperspectivefromsitcandaacr AT nicholaslbayless developmentofpreclinicalandclinicalmodelsforimmunerelatedadverseeventsfollowingcheckpointimmunotherapyaperspectivefromsitcandaacr AT jeffreyabluestone developmentofpreclinicalandclinicalmodelsforimmunerelatedadverseeventsfollowingcheckpointimmunotherapyaperspectivefromsitcandaacr AT samanthabucktrout developmentofpreclinicalandclinicalmodelsforimmunerelatedadverseeventsfollowingcheckpointimmunotherapyaperspectivefromsitcandaacr AT christianakoch developmentofpreclinicalandclinicalmodelsforimmunerelatedadverseeventsfollowingcheckpointimmunotherapyaperspectivefromsitcandaacr AT arlenehsharpe developmentofpreclinicalandclinicalmodelsforimmunerelatedadverseeventsfollowingcheckpointimmunotherapyaperspectivefromsitcandaacr
_version_	1718444458040623104

Development of preclinical and clinical models for immune-related adverse events following checkpoint immunotherapy: a perspective from SITC and AACR

Ejemplares similares